Introduction: Outcomes following renal transplantation are usually reported as graft or patient survival. However, graft function, haemoglobin and blood pressure are also important measures of quality of care. Methods: Transplant activity and incident graft survival data were obtained from NHS Blood and Transplant (NHSBT), laboratory and clinical variables and prevalent survival data were obtained from the UK Renal Registry (UKRR). Data were analysed separately for prevalent and one year post-transplant patients. Results: Increasing live and non-heartbeating donors were responsible for the increasing transplant activity. Transplant waiting list numbers continued to rise by 8%. Graft failure occurred in 3.2% of prevalent transplant patients. Death rates remained stable at 2.3/100 patient years. Malignancy accounted for 21% of these deaths. There was centre variation in outcomes such as eGFR and haemoglobin in prevalent and 1 year post-transplant recipients. Analysis of prevalent transplants by chronic kidney disease stage showed 16% with eGFR <30 and 2.2% <15. Of those in stage 5T, 26% had Hb <10 g/dl, 27% phosphate 51.8 mmol/L and 50% an iPTH 532 pmol/L. These patients were less likely to achieve the UK standards in comparison to CKD5 dialysis patients. Conclusion: Wide variations in clinical and biochemical outcomes may be secondary to variations in the care administered to transplant recipients across the UK.
Introduction
This chapter includes independent analyses regarding renal transplant activity and survival data from the Directorate of Organ Donation and Transplantation (ODT, formerly UK Transplant) within NHS Blood and Transplant (NHSBT) and analyses regarding Introduction NHSBT prospectively collects data on all relevant aspects around the episode of transplantation (donor and recipient) and also requests transplant centres to provide an annual paper based data return on the status of the recipient's graft function. This enables the organisation to generate comprehensive analysis of renal transplant activity and graft survival statistics which are regularly updated on its website.
NHSBT attributes a recipient to the centre that performed the transplant operation irrespective of where the patient is cared for before or after the procedure and hence only reports on transplant centre performance. Patients whose clinical management has been transferred back to a dialysis centre may be lost to NHSBT follow up although will still be monitored by the UKRR.
The UK Renal Registry methodology is described in chapter 15. The UKRR collects quarterly clinical data via an electronic data extraction process from hospital based renal IT systems, on all RRT patients across all their modalities until death. Comprehensive information from 1995 onwards, concerning the number of patients on the transplant waiting list, the number of transplants performed, the number of heartbeating, non-heartbeating and living donors, and patient and graft survival are available on the NHSBT website (www.uktransplant. org.uk/ukt/statistics/statistics.jsp).
Results
As of 31st December 2007, there were 8,875 patients (including adult and paediatric) active or suspended on the renal or renal plus other organ waiting list, an increase of 8% compared to 2006. During 2007, absolute numbers of live donor and non-heartbeating donor transplants continued to increase and comprised 36.2% and 13.5% of all kidney transplants performed respectively (table 5.1). Combined pancreas and kidney transplant numbers continued to increase with nearly twice as many recipients in 2007 compared to 2005 .
There was no statistically significant difference in one year and five year risk-adjusted patient and graft survival rates amongst UK renal transplant centres (table 5. 2). These graft survival rates included grafts with primary non-function (which are excluded in some countries).
Using data from the UKRR on prevalent renal only transplant patients on 1/1/2007, the death rate during 2007 was 2.3/100 patient years (CI 2.1-2.6) when cen- 
Introduction
As of 31st December 2007, 71 of the 72 adult renal centres in the UK were electronically linked to the UKRR. Only Colchester was unable to provide individual patient data, although this centre does not look after any transplant patients.
The following sections need to be interpreted in the context of variable repatriation policies: some transplant Belfast  95  96  76  84  96  100  92  100  Birmingham  90  96  84  90  91  98  91  96  Bristol  94  95  87  88  98  99  94  100  Cambridge  92  97  82  88  96  99  91  96  Cardiff  91  95  85  91  94  99  86  96  Coventry  97  97  91  89  97  100  90 centres continue to follow up and report on all patients they transplant, whereas others refer patients back to non-transplant centres for ongoing post-transplant care, some others only refer back when their graft is failing. The time post-transplantation that such referral may happen also varies between transplant centres. The UKRR is able to detect duplicate patients (being reported from both transplant and referring centre) and in such situations care is attributed to the referring centre.
Methods
Four centres (Bangor, Colchester, Wirral, Liverpool Aintree) did not have any transplant patients and were excluded from some of the analyses. Their dialysis patients were included in the relevant dialysis population denominators. Eleven centres (nine centres in Scotland, Kent and London St Georges) do not currently submit sequential laboratory data to the UKRR and were not included in the analyses on post-transplant outcomes.
Information on patient demographics (age, gender, ethnicity and primary renal diagnosis) for patients in a given renal centre were obtained from UKRR patient registration data fields. Individual patients were assigned to the centre that returned data for that particular patient during 2007. The prevalence of transplant patients in areas covered by individual primary care trust (PCT) was estimated based on the post code of the registered address for patients on RRT. Data on ethnic origin, supplied as Patient Administration System (PAS) codes, was retrieved from fields within renal centre IT systems. For the purpose of this analysis patients were grouped into Whites, South Asians, Blacks, Chinese and Others. The details of regrouping of the PAS codes into the above ethnic categories are provided in Report 2008 appendix G at www.renalreg.org. The UKRR requires a standard set of data items regarding comorbid conditions at the time of commencement of renal replacement therapy and first registration of the patient with the UKRR. The detailed methods of comorbidity data collection by the UKRR are described elsewhere [1] .
Results and discussion
Prevalent transplant numbers across the 4 nations in the UK are described in table 5.3. The prevalent patient cohort had a median time with a functioning transplant of 10.4 years.
The prevalence of renal transplant recipients in each PCT in England, Health Authority in Northern Ireland, Scotland and Wales and the proportion of prevalent patients according to modality in the renal centres across the UK are described in tables 5.4 and 5.5 respectively. After standardisation for age and gender, unexplained variability was evident in the prevalence of renal transplant recipients with some areas having higher or lower than the predicted number of prevalent transplant patients per million population. Further work to study whether this was secondary to differential access to transplantation is currently being undertaken by the UKRR.
The relative proportion of prevalent RRT patients with a transplant versus those on dialysis has been stable since at least 2000. While the proportion of patients on HD has been increasing, the proportion (and total numbers) on PD has been falling. However, the increasing transplant activity has not been able to keep pace with the number of patients joining the national organ waiting list, which has grown much more rapidly since 2004 when the UKRR first started reporting the variation between centres in the percentage of dialysis patients on the national transplant waiting list.
Age and gender
The gender ratio amongst incident and prevalent transplant patients has remained stable since 2002 (table 5.6 and figure 5.1). Whilst the median age of incident transplant patients has not changed much since 2002, there has been a small but steady increase in the median age of prevalent transplant patients, suggesting but not proving, that survival after renal transplantation has improved in the UK over the last 6 years.
Primary renal diagnosis
The number of patients achieving simultaneous kidney-pancreas (SPK) transplantation has increased by more than 200% since 2003 and this was reflected in Ravanan/Udayaraj/Steenkamp/Ansell c76 the increasing number of diabetic patients with a functioning transplant amongst incident dialysis patients as shown in table 5.7. If this trend of increasing transplantation activity for diabetics continues, there will be an inevitable decrease in the relative proportion of incident non-diabetic patients receiving a renal transplant.
Ethnicity
It was difficult to compare the proportion of patients within each ethnic group receiving a transplant to those commencing dialysis from the same group because data on ethnicity were missing in a considerable number of patients and were classified as ethnicity 'unknown' (table 5.8).
Comorbidity
Although most renal centres' renal IT system contained fields for annual comorbidity data capture, these fields were mostly incomplete. The UKRR therefore has not attempted to analyse the development of comorbidity after the start of RRT. Based on data analysis from Abrdn  452  47  8  45  Airdrie  230  64  10  26  Antrim  200  65  8  28  B Heart  578  67  6  27  Bangor  98  66  34  0  Basldn  205  64  15  20  Bradfd  395  45  11  44  Brightn  685  49  13  39  Carlis  202  43  6  51  Carsh  1,165  48  11  41  Chelms  188  57  22  20  Clwyd  155  46  12  42  Colchr  100  100  0  0  D & Gall  77  65  21  14  Derby  301  68  26  6  Derry  62  84  6  10  Donc  107  54  36  10  Dorset  442  36  13  50  Dudley  255  45  24  31  Dundee  376  45  8  47  Dunfn  220  51  11  38  Exeter  664  45  12  42  Glouc  326  54  10  36  Hull  672  46  13  40  Inverns  207  41  19  40  Ipswi  283  36  18  47  Kent  627  46  16  38  Klmarnk  214  61  22  17  L Kings  712  48  12  40  Liv Ain  115  100  0  0  M Hope  759  42  18  40 Ravanan/Udayaraj/Steenkamp/Ansell c78 patients where appropriate comorbidity information was available, it was not surprising to find that transplanted patients had none or fewer comorbidities compared to patients who remained on dialysis or had died (table 5.9). If all renal centres consistently reported on the comorbidity of their RRT patients it would be possible to compare whether inter-centre differences exist in wait-listed and transplanted patients by comorbidity.
Dialysis centres

Post-transplant follow-up
Introduction There continued to be a huge variation in the extent of completeness of data (tables 5.10a and b) reported by each centre. Better data returns would facilitate more meaningful comparisons between centres and help to determine the causes of differences between centres in Norwch  170  92  93  91  91  22  Nottm  442  98  93  96  96  83  Oxford  796  96  77  95  95  38  Plymth  233  93  92  94  92  16  Ports  665  84  52  83  79  7  Prestn  350  89  85  89  86  52  Redng  214  99  100  99  98  81  Sheff  496  99  74  99  99  17  Shrew  78  100  96  96  95  60  Stevng  174  84  80  83  82  47  Sthend  53  100  94  96  96  15  Stoke  230  97  99  97  97  30  Sund  99  98  76  98  93  79  Swanse  155  98  98  98  98  39  Truro  101  97  77  98  98  50  T y r o n e  6 1  8 5  9 8  9 2  9 2  2 6  Ulster  3  100  100  100  100  33  Wolve  104  97  85  98  86  63 Ravanan/Udayaraj/Steenkamp/Ansell c82 were excluded as they did not submit biochemical data to the UKRR, Belfast and Manchester RI have only recently commenced submitting data to the UKRR and were therefore also excluded. After excluding these 5 from the 23 transplant centres, one year outcomes are described for 18 transplant centres across the UK.
Methods
Data for key laboratory variables are reported for all prevalent patients with valid data returns for a given renal centre (both transplanting and non-transplanting centres) and for one year post-transplant results for patients transplanted 2000-2006 with patients attributed to the transplant centre that performed the procedure.
Time post-transplantation may have a significant effect on key biochemical and clinical variables and this is likely to be independent of a centre's clinical practices. Therefore inter-centre comparison of data on prevalent transplant patients is open to bias. To minimise such bias, outcomes are also reported in patients one year post-transplantation. It is presumed that patient selection policies and local clinical practices are more likely to be relevant in influencing outcomes 12 months post-transplant and therefore comparison of outcomes between centres are more robust. It should be noted that several dialysis centres only receive patients back to their clinical care when the graft is failing.
Prevalent patient data
Data from both transplanting and non-transplanting renal centres concerning biochemical and clinical variables for patients with a functioning transplant were included in the analyses. The cohort comprised of prevalent patients as on 31/12/ 2007. Patients were assigned to the renal centre that sent the data to the UKRR but some patients will have received care in more than one centre. If data for the same transplant patient were received from both the transplant centre and nontransplant centre, care was allocated to the non-transplant centre. Patients for whom the exact date of transplant was not known were excluded from analyses. 
Estimated glomerular filtration rate (eGFR)
For the purpose of eGFR calculation, the 4-variable MDRD formula was used, although serum creatinine has not been standardised to that of the assay used at the MDRD laboratory, and the different creatinine assay methods in use in the UK have not been taken into account. The majority of UK NHS laboratories are believed to have made appropriate adjustments taking into account differences between the Beckman assay and their current assays when reporting eGFR values. In the UK there is now a further move towards standardising against an isotope dilution mass spectrometry (ID-MS) traceable creatinine result, which will then require use of an adjusted 4v MDRD equation. The UK Association of Clinical Biochemists had stated that most UK laboratories were using the kinetic Jaffe assay and the standard 4v MDRD equation is most appropriate (personal communication, E Lamb). Patients with valid serum creatinine results but no ethnicity data were classed as White for the purpose of the eGFR calculation as few transplanted patients were from an ethnic minority.
One year post-transplant data
Patients who received a renal transplant between 1 January 2000 and 31 December 2006 were assigned according to the renal centre in which they were transplanted (table 5.11).
Brighton (until 1996) and Carshalton/St Helier's (until 2003) were transplanting centres, with subsequent transplants performed at London St George's. Patients who had died or experienced graft failure within 12 months post-transplantation were excluded from analysis. For patients with more than one transplant during 2000-2006, they were included as separate episodes provided each of the transplants functioned for a year.
For each patient, the most recent laboratory or blood pressure for the relative 4th/5th quarter (9-15 months) after renal transplantation, was taken to be representative of the one year , with 16% of prevalent transplant recipients having an eGFR <30 ml/min/1.73 m 2 . Whilst local repatriation policies on timing of transfer of care of patients with failing transplant from transplant centres to referring centres might explain some of the differences, it is notable that both transplanting and nontransplant centres feature at both ends of the scale. The accuracy of 4v MDRD in estimating GFR 560 ml/min/ 1.73 m 2 was poor and therefore a figure describing this is not included in this feature. Centres with a high prevalence of patients with eGFR <30 ml/min/1.73 m 2 were likely to expend significant resources in the management of complications related to declining renal function as well as ensuring safe transition to dialysis and/or re-transplantation. Figure 5 .4 represents the percentage of prevalent patients by centre with eGFR <30 mls/min/1.73 m 2 as a funnel plot enabling for the first time to more accurately compare outcomes in centres across the UK. The solid lines show the 2 standard deviation limits (95%) and the dotted lines the limits for 3 standard deviations (99.9%). With the 53 centres included, it would be expected by chance that 2-3 centres would fall between the 2-3 standard deviation (sd) limit (1 in 20) (1 above and 1 below) and no centres should fall outside 3 sd limits.
These data show over dispersion with 13 centres within the 2-3 sd limits with 2 above (London Barts, Swansea) and 11 below. Swansea is known to receive late repatriation of transplant patients from the Cardiff There are 3 centres who fall outside the 3 sd limits with 2 above (Liverpool RI, Portsmouth) and 1 below (Carshalton). The 2 centres that fall outside the upper 99% CI (indicating a higher than expected proportion of patients with eGFR <30 ml/min/1.73 m 2 ), interestingly are both transplant centres. eGFR in patients one year after transplantation Graft function at one year post-transplantation may predict subsequent long term graft outcome. Table 5.12 shows the proportion of prevalent transplant patients with eGFR <30 ml/min/1.73 m 2 . Both patient level variables and centre practices will influence the efficiency of graft function at one year post-transplantation. Whilst it is outside the remit of this analysis to control for patient level variables, one year graft function remained one of the most important outcome variables in renal transplantation other than survival data. Regression analysis (least squares) indicated a small upward trend (þ0.9 ml/min change in eGFR/year) in the one year post-transplant median eGFR between 2001 and 2006 ( figure 5.6 ). This suggests better graft function for patients transplanted more recently. Live donor transplantation as a proportion of the total number of transplants has been increasing year on year since 2000. Such recipients are known to have a higher one year post-transplant eGFR compared to deceased donor transplant recipients [2] . Therefore it may be possible to explain the slight upward trend seen in figure 5 .6 solely on the basis of changing donor demographics in the UK. However, due to a number of patients with missing donor information in the years 2005 and 2006 this analysis is inconclusive. In conjunction with transplant data from NHSBT, the UKRR hope it will be possible to explore this further in next year's report. Amongst individual transplant centres, only two centres (Leicester and Portsmouth) did not demonstrate a positive slope in one year post-transplant eGFR (data not shown).
Haemoglobin in prevalent transplant patients Transplant patients fall under the remit of the UK Renal Association chronic kidney disease (CKD) guidelines that all patients should have a haemoglobin concentration >10 g/dl.
A number of factors including immunosuppressive medication, graft function, ACE inhibitors for BP control, erythropoietin (EPO) use, intravenous or oral iron use, as well as centre practices and protocols for management of anaemia, affect haemoglobin levels in transplant patients. Figure 5 .7 shows the median haemoglobin from UK centres whilst figure 5.8 shows the percentage of transplant patients with a haemoglobin <10 g/dl. Centres with <20 patients or <50% completeness of haemoglobin data returns are not shown in these figures. The percentage of prevalent transplant patients with a haemoglobin <10 g/dl were analysed using a funnel plot, the solid lines showing the 2 standard deviation limit (95% limits) and the dotted lines the limits for 3 standard deviations (99.9% limits). With over 50 centres included, it would be expected by chance that 2-3 centres would fall outside the 95% (1 in 20) confidence intervals (1 above and 1 below) and no centres outside 3 sd limits. Figure 5 .9 shows 5 centres between the 2-3 sd upper limits indicating a higher than predicted prevalence of anaemia amongst prevalent transplant patients in these centres and table 5.13 shows the data for these centres. Interestingly all 5 of these centres (Cambridge, London Barts, Leicester, Liverpool, Oxford) are transplant centres. Three centres fall between the lower 2-3 sd limits (Carshalton, Sheffield, Newcastle) and 4 centres below the 3 sd limits (Wrexham, Basildon, Norwich, Cardiff) possibly indicating better than expected management of anaemia.
Haemoglobin in patients one year posttransplantation
The median one year post-transplant haemoglobin continued to remain stable at 13.0 g/dl (figure 5.10).
Blood pressure in prevalent transplant patients
In the absence of controlled trial data, opinion based recommendation from the UK Renal Association (RA) states that BP targets for transplant patients should be similar to the targets for patients with CKD i.e. systolic BP <130 mmHg and diastolic BP <80 mmHg.
As indicated in table 5.10a, completeness for blood pressure data returns was variable and only centres with >50% data returns were included for consideration. Despite this restriction, caution needs to be exercised in interpretation of these results because of the volume of missing data and potential bias, (e.g. a centre may be more likely to record and report blood pressure data electronically in patients with poor BP control).
Median systolic (figure 5.11), diastolic (figure 5.12) and percentage of patients achieving RA targets (figure 5.13) are shown. The current policy is to consider renal transplant recipients as a sub-group of the native kidney disease population and there is no current evidence to suggest otherwise that the knowledge gained from native kidney disease literature is not applicable to transplant recipients. Less than 30% of prevalent transplant patients across the UK achieved a BP of <130/80 mm Hg, and it is necessary to evaluate new ways to achieve this goal or assess whether this is realistically achievable in the majority of patients. Northern Ireland managed to attain a BP <130/80 mm Hg in 41.6% of patients and the policies used to achieve this need to be investigated. Ravanan/Udayaraj/Steenkamp/Ansell c90 opinion based RA recommendations suggest that transplant patients should be treated as having chronic kidney disease and hence at risk of cardio-vascular events and therefore by extension should achieve the same cholesterol levels.
Cholesterol in transplant patients
The primary analysis of data from the ALERT study of fluvastatin in renal transplantation showed no difference in major cardiac events compared with placebo (p ¼ 0.139) although secondary endpoints showed a 35 percent reduction in the cumulative incidence of cardiac death or first non-fatal MI (p ¼ 0.005) [3, 4] .
Analysis which included renal transplant function as a risk factor for cardiovascular disease and extending the 5 year study by 2 years suggested that patients with better control of hyperlipidaemia may suffer fewer adverse endpoints (major cardiac adverse events (p < 0.0007), cardiac death (p < 0.00005) and non-CV death (p < 0.0005), but not for stroke or non-fatal heart attack alone) compared to patients treated with placebo [5] .
The percentage of prevalent transplant recipients achieving a cholesterol level <5 mmol/L by centre and median cholesterol level one year after transplantation are described in figures 5.16 and 5.17 respectively.
Bone metabolism in transplant patients
In the absence of definitive literature concerning evaluation and management of renal bone disease in transplant recipients, guidelines derived from chronic native kidney disease are commonly used as a surrogate. It is beyond the scope of this commentary to discuss the appropriateness or otherwise of this strategy. Since there are no other widely accepted guidelines on target biochemical values concerning bone disease in transplant patients the chronic kidney disease audit measure has been adopted. With nearly 99% of prevalent patients achieving a phosphate level <1.8 mmol/L with achievement ranging from 96%-100%, this is probably not a useful clinical performance indicator and may also mask a more important problem of hypophosphataemia caused by phosphate loss post-transplantation. The achievement of calcium within the Standard varied from 95% to 60%. It is possible that late repatriation of patients with failing grafts from transplant centres may result in some selective enrichment of non-transplanting renal centres with patients who were less likely to conform to target biochemical results. However, figure 5.20 shows both transplanting and non-transplanting renal centres are represented at both ends of the graph suggesting centre practices and possibly also laboratory measurement factors may be more relevant than repatriation policies in achieving target calcium levels in transplant patients.
Serum phosphate
Serum calcium
Serum parathyroid hormone concentration
There are no definitive guidelines on the frequency with which serum iPTH should be measured in stable transplant recipients. Consequently there was very wide variability in data completeness across the UK with less than 50% of centres having iPTH measurements for the transplant patients under their care.
Analysis of data from 20 centres with measurements showed that over 50% of patients had an iPTH above the upper limit of normal (7-8 pmol/L) and the median iPTH was 10 pmol/L. The UK does not have a variable CKD stage related Standard compared with KDOQI, and more than 90% of patients achieved the target of <32 pmol/L (data not shown). However, given the extent of missing information extreme caution needs to be exercised when interpreting these data. Introduction About 3% of prevalent transplant patients returned to dialysis in 2007 and this was a similar percentage to the last 7 years. Patients presenting with native chronic kidney disease can have reasonable variability in timing of presentation to specialist care after disease initiation. This in turn can result in poorer outcomes as has been documented for late-presenters on dialysis therapies. Lack of specialist care resulting in lack of amelioration of modifiable risk factors like anaemia of CKD etc. is commonly quoted as the reason for poorer outcomes in late-presenters. Transplant recipients on the other hand are almost always followed up regularly in specialist transplant or renal clinics and it would be reasonable to expect patients with failing grafts to receive appropriate care and therefore have many of their modifiable risk factors addressed before complete graft failure and return to dialysis.
Methods
The transplant cohort consisted of prevalent transplant recipients as on 31/12/2007 (n ¼ 16,469) and where classified according to the KDIGO staging criteria with the suffix of 'T' to represent their transplant status. Patients with missing ethnicity information were classified as white for the purpose of calculating eGFR. Prevalent dialysis patients, except those who commenced dialysis in 2006, comprised the comparison dialysis cohort (n ¼ 16,252). This included 2,743 peritoneal dialysis patients. For both cohorts, the analysis used the most recent available value from the last two quarters of the 2007 laboratory data. from centres with a high rate of return for cause of death. When this was compared with an analysis of all the cause of death data on the database, the percentages in corresponding EDTA categories remained unchanged so the latter data were therefore included. The analysis of prevalent patients included all patients receiving RRT on 1/1/2007.
Results and Discussion
Causes of death in prevalent RRT patients in 2007 by modality and age Tables 5.15 and 5.16 and figure 5 .22 show the differences in the causes of death between prevalent dialysis and transplant patients. These data are neither age adjusted nor adjusted for differences in the comorbidity between the 2 groups. As expected, cardiac disease as a cause of death is less common in the transplanted patients as these are a pre-selected low risk group of patients. Treatment withdrawal still occurs in the transplanted group, in patients who choose not to restart dialysis when their renal transplant fails. In Table 5 .16, there were no differences in the causes of death between transplanted patients aged <55 or 555 years with malignancy accounting for 21% of deaths with a functioning transplant in both age groups.
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